TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: High-density cholesterol (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Delivery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Neutrophil nadirs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase in the percentage of superficial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in the maturation value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the scores of atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cosmetic results (scarring)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: first-line response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of febrile neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: MxA mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impaired driving performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased saccadic latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in PMDRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin D Activity (VDA) in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: histological recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Poor outcome (mRS score > 2)
Endpoint domain: Mortality/survival
Primary endpoint: Preference rating for Grøn Tuborg
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Correct identification of Grøn Tuborg
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prevalence rate of severe coronary disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peripheral artery buffering function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Longest period of consecutive urine samples negative for methamphetamine metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in unprotected receptive anal intercourse (URAI)
Endpoint domain: Life impact
Endpoint subdomain: Risk behaviors
Primary endpoint: arrhythmic death/cardiac arrest
Endpoint domain: Mortality/survival
Primary endpoint: ulcer-healing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: BCC reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical efficacy of the CardioMEMS hemodynamic monitoring system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of sick days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increase in viable mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of malignant ventricular arrhythmia
Endpoint domain: Adverse events/effects
Primary endpoint: Procedure failure
Endpoint domain: Adverse events/effects
Primary endpoint: Total PCI time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Serum estradiol levels in men after intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum estradiol levels in women after intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in abnormal strain pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cystitis
Endpoint domain: Adverse events/effects
Primary endpoint: Progression to Left Ventricular Hypertrophy (LVH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to stone clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain and analgesic use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate-specific antigen velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to prostate-specific antigen progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median percentage time gastric pH remained below 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AT recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Overall subjective image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in joint damage progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Severity of PMS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Frey's Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lenticular nucleus hyperechogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Severity of spasmodic dysphonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood flow increase at neuroretinal rim
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intake of energy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intake of protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of epigastric pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction of heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Brachial arterial flow-mediated dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiovagal baroreceptor sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Corneal epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of clinical and functional parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: entropy values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mid-upper arm circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean time to fracture union
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall improvement in physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ankle plantarflexor spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait pattern improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self reports of wheezing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: hospital admissions for respiratory conditions
Endpoint domain: Adverse events/effects
Primary endpoint: Eprosartan maximum concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time‐zero to the last quantifiable concentration (AUC0‐t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal clearance (Cl(r))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Anemia recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to anemia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of body levels of iron (ferritin and transferrin saturation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: average time to perform 10 stands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: angiographic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of hospital days reimbursed by Medicaid
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of pediatric intensive care days reimbursed by Medicaid
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proficiency of ignoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proficiency of updating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Response conflict performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Radiographic periimplant bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to bony healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute myocardial infarction/non-ST segment elevation myocardial infarction (AMI/NSTEMI)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of acute respiratory distress syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Survival after nephrectomy
Endpoint domain: Mortality/survival
Primary endpoint: Likelihood of response to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TV reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of permanent hypothyroidism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 24-hour ambulatory BP control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: daytime change in SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: nighttime change in SBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MfERG amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma AOPP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GPx levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle-brachial index improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Increase in claudication distance (ACD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myocardial ATP content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: rectal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: use of incontinence pads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: rectal discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Serum Q10 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum selenium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of intensive care
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Positive perception of communication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: agonist‐induced platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for rizatriptan ODT over sumatriptan
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain relief after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain-free status at 60 and 120 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial ischemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased risk of arrhythmic death
Endpoint domain: Mortality/survival
Primary endpoint: Risk of placental malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to randomization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Parental distress around HIV disclosure
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: consistent condom use in the past 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of weeks women were abstinent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute rejection confirmed by biopsy
Endpoint domain: Adverse events/effects
Primary endpoint: p24 antigen level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety (no neutropenia or anemia)
Endpoint domain: Adverse events/effects
Primary endpoint: AKPS (Anterior Knee Pain Scale)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Duration of low interstitial glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eating disorders symptomatology reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical impairment reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Median time to first AV graft reintervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AV graft discontinuation or abandonment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incontinence rates after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 18-month activity levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in hyperdynamic facial lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: left PFC baseline gray matter volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: marginal adaptation and discoloration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of abdominal pain AEs
Endpoint domain: Adverse events/effects
Primary endpoint: 3 consecutive weeks of abstinence from cocaine and alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean submucosal injection volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Additional submucosal injection requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Decrease in sputum eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in serum IgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fewer exacerbations requiring oral cortico‐steroids
Endpoint domain: Adverse events/effects
Primary endpoint: Agreement on QRS interval measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 12-item Short Form Survey physical composite score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 12-item Short Form Survey mental composite score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vaginal delivery within 12 h of admission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean hospital costs per woman
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Predelivery inpatient hours
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean pain score during injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subconjunctival haemorrhage incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in cardiovascular-related emergency room visits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in hospitalization days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in cost of care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Elimination of the need for tube feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with n-3 LC PUFAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immediate cognitive adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of Life (QOL) results interpretation
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Duration of parturition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: medication consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: healthcare resources use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to return to sport activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding at 2 weeks
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parenting sense of competence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rates of suicidality
Endpoint domain: Adverse events/effects
Primary endpoint: Postprocedure pancreatitis occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Median peak amylase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median peak lipase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost of antibiotic regimens
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean diarrhea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: IBS-QOL score (Item 28)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative risk of pressure ulcers (PUs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in HIV TRB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of PASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ICU hospitalization length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospital readmission rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUC(∞) of vardenafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) of vardenafil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin status in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IV placement rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3/4 adverse events related to bevacizumab
Endpoint domain: Adverse events/effects
Primary endpoint: shoulder subluxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: contracture of shoulder external rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total heparin dose required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heparin dose per kilogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caloric intake from snacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reaction times after caffeine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean log10-reduction of bacterial count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Death through 180 days
Endpoint domain: Mortality/survival
Primary endpoint: Heart failure rehospitalization through 60 days
Endpoint domain: Mortality/survival
Primary endpoint: Death or cardiovascular or renal rehospitalization through day 60
Endpoint domain: Mortality/survival
Primary endpoint: Mean change in FEF75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nitroglycerin-mediated endothelium-independent vasodilation (NMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: complete or near-complete sterilization of the operative specimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: mean number of medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: hypotony with wound leak
Endpoint domain: Adverse events/effects
Primary endpoint: Acquisition of any antibiotic‐resistant gram‐negative bacteria
Endpoint domain: Adverse events/effects
Primary endpoint: STH prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total immunoglobulin E (IgE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: End-expiratory lung volume (EFL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Borg dyspnea scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes